People with private insurance are most likely to be able to get prescription weight loss drugs covered. Less than 10% of people who got semaglutide last year were on Medicaid.
The FDA’s approval of Eli Lilly’s Zepbound could signal more insurers paying for the use of such drugs. Demand is great so the costs could be big and push up premiums.
